
Yuhan secures US patent for lung cancer drug lazertinib, blocking copycats
Korea’s Yuhan Corp. is tightening its grip on U.S. rights to its homegrown EGFR inhibitor lazertinib, branded locally as Leclaza and overseas as Lazcluze, by securing a new formulation patent aimed at keeping generics at bay even after core exclusivity …